These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947 [TBL] [Abstract][Full Text] [Related]
14. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498 [TBL] [Abstract][Full Text] [Related]
15. Portopulmonary hypertension in the current era of pulmonary hypertension management. Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258 [TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. Farber HW; Miller DP; Meltzer LA; McGoon MD J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189 [TBL] [Abstract][Full Text] [Related]
17. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Strange G; Lau EM; Giannoulatou E; Corrigan C; Kotlyar E; Kermeen F; Williams T; Celermajer DS; Dwyer N; Whitford H; Wrobel JP; Feenstra J; Lavender M; Whyte K; Collins N; Steele P; Proudman S; Thakkar V; Keating D; Keogh A; Heart Lung Circ; 2018 Nov; 27(11):1368-1375. PubMed ID: 29029950 [TBL] [Abstract][Full Text] [Related]
18. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA; BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502 [TBL] [Abstract][Full Text] [Related]
20. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. Olsson KM; Richter MJ; Kamp JC; Gall H; Heine A; Ghofrani HA; Fuge J; Ewert R; Hoeper MM J Heart Lung Transplant; 2019 Jul; 38(7):748-756. PubMed ID: 31128966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]